IN THE CLAIMS

This listing of claims provided below will replace all prior versions and listings of claims in the application.

1.126

Claims 1-25 (canceled)

- Claims 1-25 (canceled)

 25

 26. (new) A composition comprising a first ester prodrug of florfenicol, a second ester prodrug of florfenicol, and a pharmaceutically acceptable carrier, wherein the composition is an injectable composition.
- 26. (new) The composition of claim 26, wherein the concentration of the prodrugs of florfenicol in the composition is at least about 200 mg/mL.
- 27, 28. (new) The composition of claim 26, wherein at least one of the ester prodrugs of florfenicol is an ester formed between florfenicol and a carboxylic acid.
- 28. (new) The composition of claim 26, wherein both the first ester prodrug of florfenicol and the second ester prodrug of florfenicol are an ester formed between florfenicol and a carboxylic acid.
- 236. (new) The composition of claim 26, wherein the first ester prodrug of florfenicol and the second ester prodrug of florfenicol are selected from the group consisting of florfenicol acetate, florfenicol propionate, florfenicol butyrate, florfenicol pentanoate, florfenicol hexanoate, florfenicol heptanoate, florfenicol octanoate, florfenicol nanoate, florfenicol decanoate, florfenicol undecanoate, florfenicol dodecanoate, and florfenicol phthalate.
- 30 31. (new) The composition of claim 30, wherein the first ester prodrug of florfenicol and the second ester prodrug of florfenicol are selected from the group consisting of florfenicol acetate, florfenicol propionate, florfenicol butyrate, florfenicol hexanoate, florfenicol phthalate.
- 22. (new) The composition of claim 26, wherein the composition forms a drug depot when injected into a mammal.

DC01 643893 vi

- 32. (new) The composition of claim 26, wherein the pharmaceutically acceptable carrier is selected from the group consisting of N-methyl pyrrolidone, pyrrolidone, polyethylene glycol, propylene glycol, glycerol formal, isosorbid dimethyl ether, ethanol, dimethyl sulfoxide, tetrahydrofurfuryl alcohol, triacetin, and combinations thereof.
- 32. (new) The composition of claim 33, wherein the pharmaceutically acceptable carrier is selected from the group consisting of propylene glycol, glycerol formal, and combinations thereof.
- 35. (new) A composition comprising florfenical butyrate and a pharmaceutically acceptable solvent selected from N-methyl pyrrolidone, pyrrolidone, polyethylene glycol, propylene glycol, glycerol formal, isosorbid dimethyl ether, ethanol, dimethyl sulfoxide, tetrahydrofurfuryl alcohol, triacetin, and combinations thereof, wherein the composition is injectable.
- 36. (new) The composition of claim 35, wherein the solvent is selected from propylene glycol, glycerol formal, and combinations thereof.
- 36, (new) The composition of claim 36, wherein the pharmaceutically acceptable carrier is a combination of propylene glycol and glycerol formal.
- 31/ 38. (new) The composition of claim 35, wherein the concentration of florfenicol butyrate in the composition is at least about 200 mg/mL.
- 38. (new) A method of treating a bacterial infection in a feline comprising injecting the feline with the pharmaceutical composition of claim 26. 25
- 37 40. (new) A method of treating a bacterial infection in a feline comprising injecting the feline with the pharmaceutical composition of claim 27.26
- 40. (new) A method of treating a bacterial infection in a feline comprising injecting the feline with the pharmaceutical composition of claim 28. 27
- 42. (new) A method of treating a bacterial infection in a feline comprising injecting the feline with the pharmaceutical composition of claim 29.

43. (new) A method of treating a bacterial infection in a feline comprising injecting the feline with the pharmaceutical composition of claim 30.29

43
A4. (new) A method of treating a bacterial infection in a feline comprising injecting the feline with the pharmaceutical composition of claim 21.30

(new) A method of treating a bacterial infection in a feline comprising injecting the feline with the pharmaceutical composition of claim 35. 32

(new) A method of treating a bacterial infection in a feline comprising injecting the feline with the pharmaceutical composition of claim 35. 34

M. (new) A method of treating a bacterial infection in a feline comprising injecting the feline with the pharmaceutical composition of claim 36. 35

47. (new) A method of treating a bacterial infection in a feline comprising injecting the feline with the pharmaceutical composition of claim 37. 36

(new) A method of treating a bacterial infection in a feline comprising injecting the feline with the pharmaceutical composition of claim 28. 37